Table of Contents Author Guidelines Submit a Manuscript
Critical Care Research and Practice
Volume 2017 (2017), Article ID 3598392, 6 pages
https://doi.org/10.1155/2017/3598392
Clinical Study

IVC Measurements in Critically Ill Patients with Acute Renal Failure

University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA

Correspondence should be addressed to Houssein A. Youness; ude.cshuo@ssenuoy-niessuoh

Received 21 February 2017; Revised 19 July 2017; Accepted 2 August 2017; Published 5 September 2017

Academic Editor: Samuel A. Tisherman

Copyright © 2017 Rami Jambeih et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Objective. To determine whether the inferior vena cava (IVC) measurement by bedside ultrasound (US-IVC) predicts improvement in renal function in patients with acute kidney injury (AKI). Design. Prospective observational study. Setting. Medical intensive care unit. Patients. 33 patients with AKI were included. Intervention. US-IVC was done on admission. The patients’ management was done by the primary teams, who were unaware of the US-IVC findings. Two groups of patients were identified. Group 1 included patients who were managed in concordance with their US-IVC (potential volume responders who had a positive fluid balance at 48 h after admission and potential volume nonresponders who had an even or negative fluid balance at 48 hours after admission). Group 2 included patients in whom the fluid management was discordant with their US-IVC. Measurements and Main Results. At 48 hours, Group 1 patients had a greater improvement in creatinine [85% versus 31%, ], creatinine clearance (% versus %, ), and urine output ( versus  ml/Kg/h, ). Conclusion. In critically ill patients with AKI, concurrence of fluid therapy with IVC predicted fluid management, as assessed by bedside ultrasound, was associated with improved renal function at 48 hours. This trial is registered with ClinicalTrials.gov registration number: NCT02064244.